John Kelton

List of Publications by Year in descending order

93 papers	10,939 citations	101543 36 h-index	54911 84 g-index
94 all docs	94 docs citations	94 times ranked	4148 citing authors

#	Article	IF	Citations
1	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. New England Journal of Medicine, 1995, 332, 1330-1336.	27.0	2,664
2	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-1708.	1.4	976
3	Temporal Aspects of Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2001, 344, 1286-1292.	27.0	925
4	A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine, 1996, 101, 502-507.	1.5	872
5	Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis. Annals of Internal Medicine, 2001, 135, 502.	3.9	429
6	Argatroban Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Archives of Internal Medicine, 2003, 163, 1849.	3.8	396
7	An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients. Archives of Internal Medicine, 2003, 163, 2518.	3.8	287
8	Antiâ€“platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 2005, 106, 3791-3796.	1.4	271
9	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. Translational Research, 2005, 146, 341-346.	2.3	261
10	Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature, 2021, 596, 565-569.	27.8	218
11	Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood, 2001, 98, 1842-1846.	1.4	198
12	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood, 2000, 96, 188-194.	1.4	190
13	Treatment of Heparin-Induced Thrombocytopenia. Archives of Internal Medicine, 2004, 164, 361.	3.8	184
14	Heparinâ€induced thrombocytopenia and thrombosis: clinical and laboratory studies. British Journal of Haematology, 1993, 84, 322-328.	2.5	175
15	Heparin-induced thrombocytopenia: a historical perspective. Blood, 2008, 112, 2607-2616.	1.4	172
16	A prospective study to determine the frequency and clinical significance of alloimmunization postâ€transfusion. British Journal of Haematology, 1995, 91, 1000-1005.	2.5	159
17	Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 385, 720-728.	27.0	156
18	A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia. American Journal of Medicine, 2008, 121, 632-636.	1.5	154

#	Article	IF	Citations
19	The epitope specificity of heparinâ€induced thrombocytopenia. British Journal of Haematology, 1996, 95, 161-167.	2.5	152
20	The platelet serotoninâ€release assay. American Journal of Hematology, 2015, 90, 564-572.	4.1	138
21	High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematology,the, 2016, 3, e489-e496.	4.6	131
22	A diagnostic test for heparinâ€induced thrombocytopenia: detection of platelet microparticles using flow cytometry. British Journal of Haematology, 1996, 95, 724-731.	2.5	125
23	Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2013, 368, 737-744.	27.0	107
24	Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematology,the, 2015, 2, e75-e81.	4.6	99
25	The Pathophysiology of Heparin-Induced Thrombocytopenia. Chest, 2005, 127, 9S-20S.	0.8	96
26	Studies on the frequency of heparin-associated thrombocytopenia. Thrombosis Research, 1984, 33, 439-443.	1.7	80
27	Plateletâ€activating immune complexes identified in critically ill COVIDâ€19 patients suspected of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2021, 19, 1342-1347.	3.8	74
28	Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1990, 74, 457-464.	2.5	71
29	Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. Chest, 2011, 140, 366-373.	0.8	69
30	A prospective comparison of four techniques for measuring plateletâ€associated IgG. British Journal of Haematology, 1989, 71, 97-105.	2.5	55
31	Laboratory abnormalities in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1998, 103, 1031-1036.	2.5	55
32	The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and metaâ€analysis of a diagnostic test. Journal of Thrombosis and Haemostasis, 2019, 17, 787-794.	3.8	51
33	Neonatal alloimmune thrombocytopenia: Spontaneous in utero intracranial hemorrhage. American Journal of Hematology, 1988, 28, 98-102.	4.1	46
34	A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing. British Journal of Haematology, 1992, 81, 579-584.	2.5	42
35	Platelet IgG Fc receptor. American Journal of Hematology, 1987, 25, 299-310.	4.1	39
36	Factor V Leiden and Thrombotic Complications in Heparin-induced Thrombocytopenia. Thrombosis and Haemostasis, 1998, 79, 50-53.	3.4	37

#	Article	IF	Citations
37	Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. Viruses, 2021, 13, 697.	3.3	36
38	The Serological Investigation of Patients with Autoimmune Thrombocytopenia. Thrombosis and Haemostasis, 1995, 74, 228-233.	3.4	35
39	HLAâ€DR expression by platelets in acute idiopathic thrombocytopenic purpura. British Journal of Haematology, 1992, 81, 552-557.	2.5	33
40	Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 389-399.	3.8	33
41	The effect of rituximab on antiâ€platelet autoantibody levels in patients with immune thrombocytopenia. British Journal of Haematology, 2017, 178, 302-307.	2.5	32
42	A phaseâ€II sequential caseâ€series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. British Journal of Haematology, 2015, 170, 208-217.	2.5	31
43	Lessons from vaccine-induced immune thrombotic thrombocytopenia. Nature Reviews Immunology, 2021, 21, 753-755.	22.7	27
44	Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1987, 66, 509-513.	2.5	26
45	Pitfalls in the diagnosis of heparinâ€induced thrombocytopenia: A 6â€year experience from a reference laboratory. American Journal of Hematology, 2015, 90, 629-633.	4.1	26
46	How do we diagnose immune thrombocytopenia in 2018?. Hematology American Society of Hematology Education Program, 2018, 2018, 561-567.	2.5	25
47	Megakaryocyte apoptosis in immune thrombocytopenia. Platelets, 2018, 29, 729-732.	2.3	24
48	Quantitation of red cell membrane associated immunoglobulin in children with Plasmodium falciparum parasitaemia. British Journal of Haematology, 1983, 54, 567-572.	2.5	22
49	Comparison of the measurement of surface or total platelet-associated IgG in the diagnosis of immune thrombocytopenia. American Journal of Hematology, 1985, 18, 1-5.	4.1	21
50	Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. Blood Coagulation and Fibrinolysis, 2008, 19, 471-475.	1.0	21
51	Novel treatments for immune thrombocytopenia. Presse Medicale, 2014, 43, e87-e95.	1.9	21
52	Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. British Journal of Haematology, 2018, 181, 234-241.	2.5	21
53	Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. American Journal of Hematology, 2004, 77, 387-390.	4.1	19
54	Heparin-Induced Thrombocytopenia: An Iceberg Rising. Mayo Clinic Proceedings, 2005, 80, 988-990.	3.0	19

#	Article	IF	Citations
55	Current Concepts in the Treatment of Immune Thrombocytopenia. Drugs, 1990, 40, 531-542.	10.9	18
56	Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1996, 93, 421-426.	2.5	18
57	Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment?. Transfusion, 2002, 42, 388-392.	1.6	18
58	Development of a high-yield expression and purification system for platelet factor 4. Platelets, 2018, 29, 249-256.	2.3	18
59	Characteristics of VITT antibodies in patients vaccinated withÂAd26.COV2.S. Blood Advances, 2023, 7, 246-250.	5.2	18
60	The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Advances, 2022, 6, 4228-4235.	5.2	18
61	The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. British Journal of Haematology, 1995, 91, 742-746.	2.5	17
62	Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. Chest, 2018, 153, 1396-1404.	0.8	16
63	Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematology,the, 2020, 7, e640-e648.	4.6	16
64	Alloimmune neonatal thrombocytopenia associated with incidental maternal thrombocytopenia. American Journal of Hematology, 1990, 35, 43-44.	4.1	15
65	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 2082-2088.	3.8	14
66	Producing megakaryocytes from a human peripheral blood source. Transfusion, 2016, 56, 1066-1074.	1.6	12
67	The use of antiâ€Ð to improve postâ€transfusion platelet response: a randomized trial. British Journal of Haematology, 1995, 89, 163-168.	2.5	11
68	Increased cytotoxic potential of CD8⁺T cells in immune thrombocytopenia. British Journal of Haematology, 2020, 188, e72-e76.	2.5	11
69	Platelet fragments do not contribute to elevated levels of platelet associated IgG. British Journal of Haematology, 1985, 61, 707-715.	2.5	10
70	Antibody binding to megakaryocytes inÂvivo in patients with immune thrombocytopenia. European Journal of Haematology, 2015, 95, 532-537.	2.2	10
71	A comparative study of platelet factor 4â€enhanced platelet activation assays for the diagnosis of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2021, 19, 1096-1102.	3.8	10
72	SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia. Blood Advances, 2022, 6, 2250-2253.	5.2	10

#	Article	IF	Citations
73	Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. Transfusion, 2016, 56, 73-79.	1.6	8
74	A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. Platelets, 2019, 30, 1017-1021.	2.3	6
75	Immune haemolytic anaemia and thrombocytopenia: drugs and autoantibodies. Biochemical Society Transactions, 1991, 19, 183-186.	3.4	5
76	Bacterial infectionâ€associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies. British Journal of Haematology, 1995, 90, 332-335.	2.5	5
77	PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA. British Journal of Haematology, 1997, 97, 762-767.	2.5	5
78	Measurement of endogenous and exogenous alphaâ€granular platelet proteins in patients with immune and nonimmune thrombocytopenia. British Journal of Haematology, 1999, 106, 762-770.	2.5	5
79	The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia. Thrombosis Research, 2020, 194, 135-141.	1.7	5
80	Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria. British Journal of Haematology, 2021, 194, 439-443.	2.5	5
81	Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia. Blood Advances, 2021, 5, 4256-4264.	5.2	4
82	PATHOPHYSIOLOGY OF HEPARINâ€INDUCED THROMBOCYTOPENIA. British Journal of Haematology, 1992, 82, 778-779.	2.5	3
83	PLATELET AUTOANTIBODIES IN SEPTICAEMIA. British Journal of Haematology, 1985, 61, 589-591.	2.5	1
84	Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia. Blood, 2016, 128, 2548-2548.	1.4	1
85	Immune-mediated thrombocytopenia. , 2002, , 542-555.		0
86	An Algorithm for â€œIndeterminateâ€•Test Results in the Platelet Serotonin Release Assay for Heparin-Induced Thrombocytopenia (HIT).. Blood, 2006, 108, 1048-1048.	1.4	0
87	Incidence of HPA-9b in Testing for Neonatal Alloimmune Thrombocytopenia.. Blood, 2007, 110, 3214-3214.	1.4	0
88	Peripartum Management of Women with Suspected Hereditary Thrombocytopenia.. Blood, 2007, 110, 3224-3224.	1.4	0
89	An Individual Platelet Count Set-Point in ITP: A Concept Learned from Patients with Mild Thrombocytopenia and a Good Response to IVIg or Corticosteroids.. Blood, 2007, 110, 3926-3926.	1.4	0
90	The Utility of Bone Marrow Examinations for the Diagnosis of Immune Thrombocytopenia.. Blood, 2010, 116, 3691-3691.	1.4	0

#	Article	IF	Citations
91	Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study. Blood, 2010, 116, 392-392.	1.4	0
92	Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests,. Blood, 2011, 118, 3304-3304.	1.4	0
93	Persistent Impairments in Humoral and Cellular Immunity in Patients with Immune Thrombocytopenia Treated with Rituximab: A Sub-Study of a Randomized Controlled Trial. Blood, 2012, 120, 492-492.	1.4	0